In what was being dubbed as the last major big market cap event of the year, Novo Nordisk has now disclosed the results of the phase 3 trial for its experimental weight loss drug, CagriSema, which failed to meet the market’s lofty expectations. For the benefit of those who might not be aware, Glucagon-Like Peptide-1 (GLP-1) hormone suppresses hunger by stimulating the release of insulin in the pancreas, blocking the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slowing gastric emptying to reduce the overall intake of food. Novo Nordisk’s CagriSema drug combines […]
Read full article at https://wccftech.com/novo-nordisk-on-track-for-the-worst-day-since-2002-as-its-under-trial-oral-weight-loss-drug-disappoints-meets-goldmans-disaster-threshold/
